All companies
Visit website
FIBROBIOLOGICS
PublicFibroBiologics, Inc.
Healthcare · Founded 2021
The future of cell therapy
Post-money valuation ⓘ
$257.6M
As of Apr 2023 · from FibroBiologics Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$4,929,105
Across 1 round since 2023
Latest share price
$1.10
FibroBiologics Preferred Stock 1 offering price
Financials
FY2020–FY2025 · from SEC filings · hover any figure for its source$0
−$1.2M
2020
$0
−$1.6M
2021
−$5.1M
2022
−$16.5M
2023
−$11.2M
2024
−$18.6M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022 audited
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
$0
—
—
—
—
Cost of goods sold
$0
$0
—
—
—
—
Net income
-$1,169,000
-$1,582,000
-$5,121,000
-$16,485,000
-$11,161,000
-$18,646,000
Taxes paid
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$407,000
$2,266,000
$9,163,000
$13,985,000
$4,894,000
Accounts receivable
$0
$0
$300,000
$300,000
—
—
Total assets
$0
$468,000
$4,824,000
$11,821,000
$16,445,000
$9,619,000
Short-term debt
$0
$1,758,000
$300,000
—
$9,168,000
$0
Long-term debt
$0
$0
—
—
—
—
Total liabilities
$0
$1,758,000
$8,820,000
$10,568,000
$13,710,000
$3,463,000
Other
Headcount
—
5
—
—
—
—
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$257.6M
post-money
FibroBiologics Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $4.9M / $5MInvestors 718Post-money $257.6M
Reg CF annual-report compliance
Not requiredBecame a public company
Filed 1 of 4 annual reports (FY2022–FY2025)
718 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 21 filings on EDGARSource: ManualCIK 0001958777Share price $1.10
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.